Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study

Overview of attention for article published in Human Mutation, January 2010

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#44 of 3,476)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 3 news outlets
wikipedia: 2 Wikipedia pages

reddit: 1 Redditor

Readers on

mendeley: 228 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 3 news stories from 3 outlets.

Embattled Clovis Oncology Files for Chapt. 11, Sells Radioligand Therapeutic to Novartis

BioSpace, 12 Dec 2022

Courtesy of Clovis Oncology filed for Chapter 11 bankruptcy and will sell its assets through a supervised process.

Opinion | Allowing 23andMe To Test For BRCA May Do More Harm Than Good

Huffington Post, 30 Mar 2018

The Food and Drug Administration announced this month it would allow genetic testing company 23andMe to resume direct-to-consumer…

Allowing 23andMe To Test For BRCA May Do More Harm Than Good

Yahoo!, 30 Mar 2018

23AndMe is adding a BRCA test to its broader genetic screening product. More The Food and Drug Administration announced this…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.